HLA-haploidentical umbilical cord blood stem cell transplantation in a child with advanced leukemia: Clinical outcome and analysis of hematopoietic recovery

R. Miniero, A. Busca, M. G. Roncarolo, M. Saitta, A. Iavarone, F. Timeus, A. Biondi, A. Amoroso, L. Perugini, E. Ciuti, P. Saracco, L. Ruggieri, E. Vassallo, V. Gabutti, E. Madon

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Growing attention has been focused on cord blood as a source of transplantable hematopoietic stem cells. However, clinical experience is rather limited. In this study we describe a child with advanced acute lymphoblastic leukemia who received an HLA-haploidentical cord blood transplant. The patient was transplanted in third complete remission after conditioning with fractionated total body irradiation, thiotepa and cyclophosphamide. Forty-one milliliters of cryopreserved umbilical cord blood, containing 0.15 x 108 nucleated cells/kg and 0.25 x 104 CFU-GM/kg, were infused. Cyclosporine and prednisone were administered for graft-versus-host disease (GVHD) prophylaxis. The patient received G-CSF from day +1 to day +35, but no improvement in granulocyte counts was observed. Therefore, administration of GM-CSF was started on day +36 to day +59, which resulted in a significant increase in white blood cells and granulocyte counts. Sustained myeloid engraftment was evidenced by a granulocyte count >0.5 x 109/l by day +41. The presence of donor-derived cells could be documented in the peripheral blood and bone marrow of the patient by cytogenetic analysis, HLA phenotyping and DNA studies. Forty-one days after transplant, clonogenic bone marrow assays showed the presence of low frequencies of primitive hematopoietic progenitor cells (BFU-E = 19/105 and CFU-GM = 8/105). The chimerism was complete and no host-derived cells could be detected. However, the engraftment was restricted to the myeloid lineage whereas lymphoid and megakaryocytic engraftments were inadequate. The immunophenotype of the patient's peripheral blood showed the presence of T lymphocytes expressing an immature phenotype (CD2+ CD3-) at day +21. Among the subset of T cells expressing the CD3 antigen, the majority were CD45RO+ memory cells and a significant proportion was positive for the activation markers CD25, CD69̄ and HLA-DR, suggesting that these T cells had been activated in vivo. On day +41, a mild cutaneous rash consistent with grade I acute GVHD resolved with steroid treatment. Unfortunately, the patient died of hepatic insufficiency and renal failure 84 days after transplantation. Autopsy showed a multiorgan failure with hepatic veno-occlusive disease (VOD). Overall, this study shows that (1) cord blood transplantation from an HLA-mismatched donor can be performed with a low risk of acute GVHD, and (2) a small volume of cord blood containing a reduced number of CFU-GM is sufficient to achieve engraftment.

Original languageEnglish
Pages (from-to)229-240
Number of pages12
JournalBone Marrow Transplantation
Volume16
Issue number2
Publication statusPublished - 1995

Fingerprint

Cord Blood Stem Cell Transplantation
Fetal Blood
Leukemia
Granulocyte-Macrophage Progenitor Cells
Graft vs Host Disease
Granulocytes
Hematopoietic Stem Cells
Hepatic Veno-Occlusive Disease
Transplantation
Bone Marrow
Tissue Donors
CD3 Antigens
Thiotepa
Hepatic Insufficiency
T-Lymphocytes
Transplants
Erythroid Precursor Cells
Chimerism
Macrophage Colony-Stimulating Factor
Whole-Body Irradiation

Keywords

  • ALL
  • Cord blood
  • HLA-haploidentical
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Miniero, R., Busca, A., Roncarolo, M. G., Saitta, M., Iavarone, A., Timeus, F., ... Madon, E. (1995). HLA-haploidentical umbilical cord blood stem cell transplantation in a child with advanced leukemia: Clinical outcome and analysis of hematopoietic recovery. Bone Marrow Transplantation, 16(2), 229-240.

HLA-haploidentical umbilical cord blood stem cell transplantation in a child with advanced leukemia : Clinical outcome and analysis of hematopoietic recovery. / Miniero, R.; Busca, A.; Roncarolo, M. G.; Saitta, M.; Iavarone, A.; Timeus, F.; Biondi, A.; Amoroso, A.; Perugini, L.; Ciuti, E.; Saracco, P.; Ruggieri, L.; Vassallo, E.; Gabutti, V.; Madon, E.

In: Bone Marrow Transplantation, Vol. 16, No. 2, 1995, p. 229-240.

Research output: Contribution to journalArticle

Miniero, R, Busca, A, Roncarolo, MG, Saitta, M, Iavarone, A, Timeus, F, Biondi, A, Amoroso, A, Perugini, L, Ciuti, E, Saracco, P, Ruggieri, L, Vassallo, E, Gabutti, V & Madon, E 1995, 'HLA-haploidentical umbilical cord blood stem cell transplantation in a child with advanced leukemia: Clinical outcome and analysis of hematopoietic recovery', Bone Marrow Transplantation, vol. 16, no. 2, pp. 229-240.
Miniero, R. ; Busca, A. ; Roncarolo, M. G. ; Saitta, M. ; Iavarone, A. ; Timeus, F. ; Biondi, A. ; Amoroso, A. ; Perugini, L. ; Ciuti, E. ; Saracco, P. ; Ruggieri, L. ; Vassallo, E. ; Gabutti, V. ; Madon, E. / HLA-haploidentical umbilical cord blood stem cell transplantation in a child with advanced leukemia : Clinical outcome and analysis of hematopoietic recovery. In: Bone Marrow Transplantation. 1995 ; Vol. 16, No. 2. pp. 229-240.
@article{a512783893f34cc280075bc17b7ee544,
title = "HLA-haploidentical umbilical cord blood stem cell transplantation in a child with advanced leukemia: Clinical outcome and analysis of hematopoietic recovery",
abstract = "Growing attention has been focused on cord blood as a source of transplantable hematopoietic stem cells. However, clinical experience is rather limited. In this study we describe a child with advanced acute lymphoblastic leukemia who received an HLA-haploidentical cord blood transplant. The patient was transplanted in third complete remission after conditioning with fractionated total body irradiation, thiotepa and cyclophosphamide. Forty-one milliliters of cryopreserved umbilical cord blood, containing 0.15 x 108 nucleated cells/kg and 0.25 x 104 CFU-GM/kg, were infused. Cyclosporine and prednisone were administered for graft-versus-host disease (GVHD) prophylaxis. The patient received G-CSF from day +1 to day +35, but no improvement in granulocyte counts was observed. Therefore, administration of GM-CSF was started on day +36 to day +59, which resulted in a significant increase in white blood cells and granulocyte counts. Sustained myeloid engraftment was evidenced by a granulocyte count >0.5 x 109/l by day +41. The presence of donor-derived cells could be documented in the peripheral blood and bone marrow of the patient by cytogenetic analysis, HLA phenotyping and DNA studies. Forty-one days after transplant, clonogenic bone marrow assays showed the presence of low frequencies of primitive hematopoietic progenitor cells (BFU-E = 19/105 and CFU-GM = 8/105). The chimerism was complete and no host-derived cells could be detected. However, the engraftment was restricted to the myeloid lineage whereas lymphoid and megakaryocytic engraftments were inadequate. The immunophenotype of the patient's peripheral blood showed the presence of T lymphocytes expressing an immature phenotype (CD2+ CD3-) at day +21. Among the subset of T cells expressing the CD3 antigen, the majority were CD45RO+ memory cells and a significant proportion was positive for the activation markers CD25, CD69̄ and HLA-DR, suggesting that these T cells had been activated in vivo. On day +41, a mild cutaneous rash consistent with grade I acute GVHD resolved with steroid treatment. Unfortunately, the patient died of hepatic insufficiency and renal failure 84 days after transplantation. Autopsy showed a multiorgan failure with hepatic veno-occlusive disease (VOD). Overall, this study shows that (1) cord blood transplantation from an HLA-mismatched donor can be performed with a low risk of acute GVHD, and (2) a small volume of cord blood containing a reduced number of CFU-GM is sufficient to achieve engraftment.",
keywords = "ALL, Cord blood, HLA-haploidentical, Stem cell transplantation",
author = "R. Miniero and A. Busca and Roncarolo, {M. G.} and M. Saitta and A. Iavarone and F. Timeus and A. Biondi and A. Amoroso and L. Perugini and E. Ciuti and P. Saracco and L. Ruggieri and E. Vassallo and V. Gabutti and E. Madon",
year = "1995",
language = "English",
volume = "16",
pages = "229--240",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - HLA-haploidentical umbilical cord blood stem cell transplantation in a child with advanced leukemia

T2 - Clinical outcome and analysis of hematopoietic recovery

AU - Miniero, R.

AU - Busca, A.

AU - Roncarolo, M. G.

AU - Saitta, M.

AU - Iavarone, A.

AU - Timeus, F.

AU - Biondi, A.

AU - Amoroso, A.

AU - Perugini, L.

AU - Ciuti, E.

AU - Saracco, P.

AU - Ruggieri, L.

AU - Vassallo, E.

AU - Gabutti, V.

AU - Madon, E.

PY - 1995

Y1 - 1995

N2 - Growing attention has been focused on cord blood as a source of transplantable hematopoietic stem cells. However, clinical experience is rather limited. In this study we describe a child with advanced acute lymphoblastic leukemia who received an HLA-haploidentical cord blood transplant. The patient was transplanted in third complete remission after conditioning with fractionated total body irradiation, thiotepa and cyclophosphamide. Forty-one milliliters of cryopreserved umbilical cord blood, containing 0.15 x 108 nucleated cells/kg and 0.25 x 104 CFU-GM/kg, were infused. Cyclosporine and prednisone were administered for graft-versus-host disease (GVHD) prophylaxis. The patient received G-CSF from day +1 to day +35, but no improvement in granulocyte counts was observed. Therefore, administration of GM-CSF was started on day +36 to day +59, which resulted in a significant increase in white blood cells and granulocyte counts. Sustained myeloid engraftment was evidenced by a granulocyte count >0.5 x 109/l by day +41. The presence of donor-derived cells could be documented in the peripheral blood and bone marrow of the patient by cytogenetic analysis, HLA phenotyping and DNA studies. Forty-one days after transplant, clonogenic bone marrow assays showed the presence of low frequencies of primitive hematopoietic progenitor cells (BFU-E = 19/105 and CFU-GM = 8/105). The chimerism was complete and no host-derived cells could be detected. However, the engraftment was restricted to the myeloid lineage whereas lymphoid and megakaryocytic engraftments were inadequate. The immunophenotype of the patient's peripheral blood showed the presence of T lymphocytes expressing an immature phenotype (CD2+ CD3-) at day +21. Among the subset of T cells expressing the CD3 antigen, the majority were CD45RO+ memory cells and a significant proportion was positive for the activation markers CD25, CD69̄ and HLA-DR, suggesting that these T cells had been activated in vivo. On day +41, a mild cutaneous rash consistent with grade I acute GVHD resolved with steroid treatment. Unfortunately, the patient died of hepatic insufficiency and renal failure 84 days after transplantation. Autopsy showed a multiorgan failure with hepatic veno-occlusive disease (VOD). Overall, this study shows that (1) cord blood transplantation from an HLA-mismatched donor can be performed with a low risk of acute GVHD, and (2) a small volume of cord blood containing a reduced number of CFU-GM is sufficient to achieve engraftment.

AB - Growing attention has been focused on cord blood as a source of transplantable hematopoietic stem cells. However, clinical experience is rather limited. In this study we describe a child with advanced acute lymphoblastic leukemia who received an HLA-haploidentical cord blood transplant. The patient was transplanted in third complete remission after conditioning with fractionated total body irradiation, thiotepa and cyclophosphamide. Forty-one milliliters of cryopreserved umbilical cord blood, containing 0.15 x 108 nucleated cells/kg and 0.25 x 104 CFU-GM/kg, were infused. Cyclosporine and prednisone were administered for graft-versus-host disease (GVHD) prophylaxis. The patient received G-CSF from day +1 to day +35, but no improvement in granulocyte counts was observed. Therefore, administration of GM-CSF was started on day +36 to day +59, which resulted in a significant increase in white blood cells and granulocyte counts. Sustained myeloid engraftment was evidenced by a granulocyte count >0.5 x 109/l by day +41. The presence of donor-derived cells could be documented in the peripheral blood and bone marrow of the patient by cytogenetic analysis, HLA phenotyping and DNA studies. Forty-one days after transplant, clonogenic bone marrow assays showed the presence of low frequencies of primitive hematopoietic progenitor cells (BFU-E = 19/105 and CFU-GM = 8/105). The chimerism was complete and no host-derived cells could be detected. However, the engraftment was restricted to the myeloid lineage whereas lymphoid and megakaryocytic engraftments were inadequate. The immunophenotype of the patient's peripheral blood showed the presence of T lymphocytes expressing an immature phenotype (CD2+ CD3-) at day +21. Among the subset of T cells expressing the CD3 antigen, the majority were CD45RO+ memory cells and a significant proportion was positive for the activation markers CD25, CD69̄ and HLA-DR, suggesting that these T cells had been activated in vivo. On day +41, a mild cutaneous rash consistent with grade I acute GVHD resolved with steroid treatment. Unfortunately, the patient died of hepatic insufficiency and renal failure 84 days after transplantation. Autopsy showed a multiorgan failure with hepatic veno-occlusive disease (VOD). Overall, this study shows that (1) cord blood transplantation from an HLA-mismatched donor can be performed with a low risk of acute GVHD, and (2) a small volume of cord blood containing a reduced number of CFU-GM is sufficient to achieve engraftment.

KW - ALL

KW - Cord blood

KW - HLA-haploidentical

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=0029097509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029097509&partnerID=8YFLogxK

M3 - Article

C2 - 7581141

AN - SCOPUS:0029097509

VL - 16

SP - 229

EP - 240

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 2

ER -